Core Insights - The launch of MYQORZO has been ongoing for about a month, with early signs being encouraging [1] - Key metrics are being monitored, with a focus on awareness among targeted cardiologists [1] Group 1: Launch Metrics - MYQORZO was launched in late January, and the company is only a month into the launch [1] - Over 90% awareness of MYQORZO has been reported among high-volume prescribers of Camzyos, indicating strong recognition in the target market [1]

Cytokinetics FY Conference Summary Company Overview - **Company**: Cytokinetics (NasdaqGS:CYTK) - **Focus**: Development and commercialization of cardiac myosin inhibitors, specifically MYQORZO (aficamten) Key Industry Insights - **Launch of MYQORZO**: - Launched in late January 2026, with early metrics showing over 90% awareness among high-volume prescribers of CAMZYOS, the existing cardiac myosin inhibitor [4][5] - Over 700 cardiologists have completed the REMS program and are already dispensing MYQORZO [5] - Initial prescriptions are coming from both established prescribers and new prescribers, indicating strong interest [5] Core Points and Arguments - **Market Awareness and Adoption**: - High awareness of MYQORZO among targeted cardiologists suggests a strong potential for adoption [4] - Early signs of interest include requests for information on switching patients from CAMZYOS to MYQORZO [5][7] - **Differentiation from Competitors**: - MYQORZO offers a different physician and patient experience, particularly in terms of speed of onset and dosing flexibility [16][20] - The promotion strategy focuses on safety, efficacy, and a unique experience for both physicians and patients [20] - **Financial Strategy**: - The company has strengthened its balance sheet through strategic partnerships and successful financing efforts, allowing for investment in both U.S. and European launches [26] - Plans to launch in Germany in Q2 2026, with ongoing investments in understanding market dynamics in Europe [25][26] Pipeline Developments - **ACACIA-HCM Study**: - Represents an opportunity for MYQORZO to demonstrate clinical safety and efficacy in non-obstructive hypertrophic cardiomyopathy (NHCM) [29] - The study is designed to address dosing challenges specific to NHCM, with a focus on maximum tolerated doses [32][34] - Positive phase 2 data has been observed, with improvements in biomarkers and patient-reported outcomes [35] - **Future Pipeline**: - Omecamtiv mecarbil is in a confirmatory phase 3 study for advanced heart failure, with a large patient population at high risk of mortality [52] - Ulacamten is being studied in heart failure with preserved ejection fraction (HFpEF), indicating a robust pipeline focused on specialty cardiology [53][54] Strategic Vision - **Independent Operations in Europe**: - Cytokinetics aims to operate independently in Europe, believing it can achieve profitability through strategic pricing and market understanding [48][49] - The company is focused on building a specialty cardiology franchise, leveraging its expertise and pipeline to create a valuable enterprise [49][50] Additional Considerations - **Potential Halo Effect**: - Success in the ACACIA-HCM study could positively influence MYQORZO sales in obstructive hypertrophic cardiomyopathy (OHCM) by reinforcing clinical efficacy [42][46] - **Long-term Goals**: - The company is committed to growing its top line responsibly while fulfilling fiduciary obligations to shareholders [58] This summary encapsulates the key points discussed during the Cytokinetics FY Conference, highlighting the company's strategic direction, market positioning, and pipeline developments.

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $17.8 million, up from $16.9 million in Q4 2024, while total revenues for the full year 2025 reached $88 million, compared to $18.5 million in 2024, primarily due to technology transfer and milestone recognition [27][28] - R&D expenses for Q4 2025 were $104.4 million, an increase from $93.6 million in Q4 2024, and for the full year, R&D expenses rose to $416 million from $339.4 million in 2024 [29] - G&A expenses for Q4 2025 were $91.7 million, compared to $62.3 million in Q4 2024, with full-year G&A expenses at $284.3 million, up from $215.3 million in 2024 [29] - The net loss for Q4 2025 was $183 million or $1.50 per share, compared to a net loss of $150 million or $1.26 per share in Q4 2024, with a full-year net loss of $785 million or $6.54 per share, compared to $589.5 million or $5.26 per share in 2024 [30] Business Line Data and Key Metrics Changes - The approval of MYQORZO represents a significant milestone, marking the company's transition to a global commercial-stage biopharmaceutical company [5][6] - The U.S. commercial launch of MYQORZO began immediately after FDA approval, with a focus on building customer support systems and marketing campaigns [10][12] - Initial customer feedback has been positive, with over 700 healthcare providers (HCPs) certified in the REMS program within three weeks of launch, indicating strong engagement and demand [13][14] Market Data and Key Metrics Changes - The company anticipates launching MYQORZO in Germany in Q2 2026, following its recent approval in the EU [7][18] - The company has engaged with key payers to ensure access for MYQORZO, aiming for Medicare access comparable to Camzyos by Q1 2026 and commercial access by Q4 2026 [17] Company Strategy and Development Direction - The company is focused on executing the launch of MYQORZO while advancing its muscle biology pipeline, with a disciplined approach to capital allocation [8][32] - The strategic priorities include launching MYQORZO in the U.S. and Europe, advancing clinical trials for aficamten, and investing in the muscle biology platform [32][33] - The company aims to achieve greater than 50% of CMI new patient preference share by the end of 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial prospects for MYQORZO, citing strong initial engagement from the cardiology community and a high level of interest in the new treatment option [6][13] - The company is closely monitoring the operating environment and is optimistic about the potential for MYQORZO to address significant unmet medical needs in obstructive HCM [7][36] Other Important Information - The company is committed to addressing disparities in access to care for patients with HCM through a three-year initiative with the American Heart Association [36] - The company plans to report top-line results from ACACIA-HCM in Q2 2026 and expects to receive potential FDA approval for the supplemental NDA for MAPLE-HCM by Q4 2026 [37] Q&A Session Summary Question: Is it true that the ACACIA-HCM study will be successful if at least one of the endpoints reaches statistical significance? - Management confirmed that the trial will be deemed positive if it hits on either or both of the pre-specified clinical trial endpoints [41][42][43] Question: Could you share any color on how long it's taking sites to get through the REMS certification for MYQORZO? - Management noted that REMS certification is a quick process, generally taking 10-20 minutes, and many HCPs were prepared to certify quickly due to prior experience with similar products [47][48][49] Question: What are the expectations for the placebo arm response in ACACIA-HCM? - Management indicated that they are blinded to the data but noted that previous studies showed minimal placebo response, and the trial is designed to focus on the difference between active and placebo responses [55][58] Question: How is the early market uptake for MYQORZO in the U.S.? - Management reported that demand is in line with expectations, with many patients ready to start treatment following approval [66][68] Question: What is the significance of a potential win in ACACIA-HCM for the broader HFpEF opportunity? - Management highlighted that success in ACACIA-HCM could inform expectations for HFpEF and the potential benefits of cardiac myosin inhibitors in that population [95][96]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $17.8 million, up from $16.9 million in Q4 2024, while total revenues for the full year 2025 reached $88 million, compared to $18.5 million in 2024 [27][28] - Net loss for Q4 2025 was $183 million or $1.50 per share, compared to a net loss of $150 million or $1.26 per share in Q4 2024; full year net loss for 2025 was $785 million or $6.54 per share, compared to a net loss of $589.5 million or $5.26 per share in 2024 [30] Business Line Data and Key Metrics Changes - The approval of MYQORZO for the treatment of obstructive HCM marks a significant milestone, with the company focusing on executing a disciplined commercial launch in the U.S. and preparing for launches in Europe [5][6] - The company has engaged over 12,000 customers, with more than 700 healthcare providers (HCPs) certified in the REMS program within three weeks of MYQORZO's availability [14][15] Market Data and Key Metrics Changes - The company anticipates a strong demand for MYQORZO, with a goal to achieve over 50% of new patient preference share in the CMI category by the end of 2026 [15][17] - In Europe, the first commercial launch of MYQORZO is planned in Germany for the second quarter of 2026, with preparations underway in other EU countries [18] Company Strategy and Development Direction - The company aims to advance its muscle biology pipeline while focusing on the launch of MYQORZO and expanding its commercial readiness in Europe [8][32] - Capital allocation priorities include launching MYQORZO, advancing the pipeline for aficamten, and investing in muscle biology programs [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the foundation being built for the specialty cardiology franchise and emphasized the importance of executing the launch of MYQORZO effectively [8][36] - The company is committed to addressing disparities in access to care for patients with HCM through initiatives in collaboration with the American Heart Association [36] Other Important Information - The company expects to report product sales of MYQORZO in Q1 2026, following its availability to patients in late January 2026 [28] - The company is on track for the top-line announcement of results from the ACACIA-HCM trial in the second quarter of 2026, which could represent a potential growth driver for MYQORZO [7][23] Q&A Session Summary Question: What defines success for the ACACIA-HCM study? - The trial will be deemed positive if it hits on either or both of the pre-specified clinical trial endpoints [41][43] Question: How long does REMS certification take for clinical centers? - REMS certification generally takes 10-20 minutes and has not been a barrier for HCPs to prescribe MYQORZO [47][48] Question: What are the expectations for placebo arm responses in ACACIA-HCM? - The placebo response is expected to be close to 0, with the trial designed to rely on the difference between active and placebo responses [55][58] Question: How is early market uptake for MYQORZO in the U.S.? - Demand is in line with expectations, with many patients held in reserve awaiting approval [65][67] Question: What is the significance of the ACACIA-HCM trial for HFpEF opportunities? - Success in ACACIA-HCM could inform the potential benefit of cardiac myosin inhibitors in HFpEF, given the overlapping pathologies [92][94]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $17.8 million, an increase from $16.9 million in Q4 2024 [24] - Total revenues for the full year 2025 were $88 million, compared to $18.5 million in 2024, primarily driven by a technology transfer to Bayer and milestone recognitions related to MYQORZO approvals [25] - Net loss for Q4 2025 was $183 million or $1.50 per share, compared to a net loss of $150 million or $1.26 per share in Q4 2024 [28] - Net loss for the full year 2025 was $785 million or $6.54 per share, compared to a net loss of $589.5 million or $5.26 per share in 2024 [28] Business Line Data and Key Metrics Changes - The approval of MYQORZO represents a significant milestone, marking the transition to a commercial-stage biopharmaceutical company [4] - The company is focused on executing a disciplined commercial launch of MYQORZO, with initial engagements from the cardiology community being encouraging [5][12] - The supplemental NDA for MAPLE-HCM was submitted to the FDA, with expectations for a review conclusion in Q4 2026 [6] Market Data and Key Metrics Changes - The company is preparing for the launch of MYQORZO in Germany in Q2 2026, following its approval in the EU [7][17] - The U.S. commercial launch of MYQORZO began immediately after FDA approval, with strong engagement from healthcare providers (HCPs) [10][12] - The company aims to achieve greater than 50% of new patient preference share in the cardiac myosin inhibitor (CMI) category by the end of 2026 [14] Company Strategy and Development Direction - The company is prioritizing the launch of MYQORZO and advancing its muscle biology pipeline with a focus on capital efficiency [8][30] - The strategic focus includes engaging with payers to ensure access to MYQORZO and preparing for subsequent European launches [16][17] - The company is committed to addressing disparities in access to care for patients with HCM through initiatives with the American Heart Association [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the foundation being built for the specialty cardiology franchise and the potential for continued growth and value creation [8] - The company is optimistic about the initial demand for MYQORZO and the engagement from HCPs, indicating a strong commercial trajectory [12][14] - Management highlighted the importance of executing ambitious plans while advancing the pipeline and delivering long-term impact for patients and shareholders [34] Other Important Information - The company reported a cash balance of approximately $1.22 billion at the end of Q4 2025, slightly down from $1.25 billion at the end of Q3 2025 [24] - R&D expenses for Q4 2025 were $104.4 million, up from $93.6 million in Q4 2024, reflecting increased clinical trial activities [26] - G&A expenses for Q4 2025 were $91.7 million, compared to $62.3 million in Q4 2024, driven by investments in commercial readiness [27] Q&A Session Summary Question: What defines success for the ACACIA-HCM study? - Success is defined as achieving statistical significance on either of the pre-specified clinical trial endpoints [39][40] Question: How long does REMS certification take for clinical centers? - REMS certification typically takes 10-20 minutes and has not been a barrier for HCPs to prescribe MYQORZO [45][46] Question: What are the expectations for placebo response in ACACIA-HCM? - The placebo response is expected to be low, based on previous studies, and the trial is designed to measure the difference between active and placebo responses [52][54] Question: How is the early market uptake for MYQORZO? - Early demand aligns with expectations, with many patients waiting for MYQORZO approval, indicating strong initial uptake [60][65] Question: Are there prescribers who are new to CMI? - The majority of REMS certified prescribers are current CMI prescribers, but there are also first-time prescribers [96]

1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; clinical trial ini ...

Core Viewpoint - Truist Securities has raised its price target on Cytokinetics, Inc. to $84 from $70 while maintaining a Buy rating, reflecting updated forecasts following the regulatory approval of MYQORZO [1] Group 1: Regulatory Approval and Market Potential - The recent approval of MYQORZO, which features a differentiated label, positions it to become a significant revenue driver in obstructive hypertrophic cardiomyopathy (oHCM) [2] - Truist updated its model to estimate worldwide peak sales for MYQORZO in oHCM at $3.7 billion, slightly below the $3.8 billion consensus estimate [2] Group 2: Revenue Projections and Launch Expectations - A steady launch of MYQORZO is expected to begin in early 2026, with performance anticipated to be at least comparable to the launch trajectory of Camzyos [3] - Truist modeled fiscal 2026 aficamten revenue at $106 million, aligning with consensus expectations [3] - Looking ahead, the analyst projects worldwide peak adjusted total revenue of $4.6 billion in 2035, marginally above the $4.5 billion consensus estimate [3]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 200 points on Monday [1] Group 2: UniFirst Corporation - Shares of UniFirst Corp rose significantly after receiving an acquisition proposal from Cintas Corporation for $275 per share in cash [1] - The acquisition offer values UniFirst at approximately $5.2 billion, representing a 64% premium over its 90-day average closing price as of December 11, 2025 [1] - UniFirst shares surged by 21.8% to $207.50 during Monday's trading session [1] Group 3: Other Notable Stock Movements - Hycroft Mining Holding Corporation shares jumped by 48.3% to $24.35 following positive drill results from its exploration program [3] - Adeia Inc gained 28.6% to $16.43 after signing a long-term media IP license agreement with Disney and raising its 2025 outlook [3] - BlackSky Technology Inc saw a 17.9% increase to $22.70 after Jefferies initiated coverage with a Buy rating and a price target of $23 [3] - Cytokinetics, Inc. shares rose by 11.2% to $69.74 after FDA approval of MYQORZO for treating adults with symptomatic obstructive hypertrophic cardiomyopathy [3]

Core Points - Cytokinetics held a conference call to discuss the FDA approval of MYQORZO [1] Group 1 - The conference call was led by Diane Weiser, the Senior Vice President of Corporate Affairs at Cytokinetics [1]